Therapy Detail

Therapy Name Pegfilgrastim
Therapy Description

Pegfilgrastim is a pegylated version of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), which enhances proliferation, differentiation, and activity of neutrophils (NCI Drug Dictionary).


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Pegfilgrastim Neulasta GCSF-SD01 Pegfilgrastim is a pegylated version of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), which enhances proliferation, differentiation, and activity of neutrophils (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03197935 Phase III Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) Recruiting
NCT01169636 Phase Ib/II Panobinostat Pegfilgrastim Carboplatin + Etoposide + Ifosfamide Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma Completed
NCT00293475 Phase Ib/II Filgrastim Pegfilgrastim Leucovorin Carboplatin + Methotrexate + Rituximab Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL Recruiting
NCT01424982 Phase II Pegfilgrastim Cytarabine + Methotrexate + Ponatinib Ponatinib + Vincristine Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Leucovorin Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Active, not recruiting
NCT01501487 FDA approved Cyclophosphamide + Docetaxel + Doxorubicin Cyclophosphamide + Epirubicin + Fluorouracil Paclitaxel Pegfilgrastim Cyclophosphamide + Docetaxel Cyclophosphamide + Doxorubicin Carboplatin + Docetaxel + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Completed
NCT00303849 Phase Ib/II Filgrastim Etoposide + Melphalan Carboplatin Pegfilgrastim Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma Recruiting
NCT02087176 Phase II Adavosertib Pegfilgrastim A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer Terminated
NCT00983398 Phase Ib/II Pegfilgrastim Filgrastim Carboplatin + Melphalan Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Suspended
NCT03136146 Phase II Cyclophosphamide Bortezomib Etoposide Rituximab Ofatumumab Clofarabine Pegfilgrastim Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) Recruiting
NCT03488225 Phase II Mercaptopurine + Methotrexate + Prednisone + Vincristine Cytarabine + Leucovorin + Methotrexate inotuzumab ozogamicin Ofatumumab Rituximab Cytarabine + Doxorubicin + Methotrexate + Vincristine Pegfilgrastim Cyclophosphamide + Dexamethasone + Mesna Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia Active, not recruiting
NCT01879085 Phase Ib/II Gemcitabine Docetaxel Pegfilgrastim Vorinostat Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Recruiting
NCT02531308 Phase II Metformin Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Pegfilgrastim Rituximab Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) Terminated
NCT01256398 Phase II Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Active, not recruiting
NCT02543255 Phase II Cabazitaxel Abiraterone + Leuprolide + Prednisone Pegfilgrastim Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) Recruiting
NCT01319981 Phase II Pegfilgrastim Imatinib Filgrastim Rituximab Doxorubicin Dexamethasone Vincristine Cyclophosphamide Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Active, not recruiting
NCT02181218 Phase I Pegfilgrastim Romidepsin Dexamethasone + Gemcitabine + Oxaliplatin Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Active, not recruiting
NCT02834403 Phase Ib/II Pegfilgrastim Docetaxel + L-NMMA L-NMMA L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients Recruiting